Background: The choice of efficient antipsychotic therapy for schizophrenia relies on a time-consuming trial-and-error approach, whereas the social and economic burdens of the disease call for faster alternatives. Material \& methods: In a search for predictive biomarkers of antipsychotic response, blood methylomes of 28 patients were analyzed before and 4 weeks into risperidone therapy. Results: Several CpGs exhibiting response-specific temporal dynamics were identified in otherwise temporally stable methylomes and noticeable global response-related differences were observed between good and bad responders. These were associated with genes involved in immunity, neurotransmission and neuronal development. Polymorphisms in many of these genes were previously linked with schizophrenia etiology and antipsychotic response. Conclusion: Antipsychotic response seems to be shaped by both stable and medication-induced methylation differences.
@article{arxiv.2304.03131,
title = {Risperidone response in patients with schizophrenia drives DNA methylation changes in immune and neuronal systems},
author = {Ana Lokmer and Charanraj Goud Alladi and Réjane Troudet and Delphine Bacq-Daian and Anne Boland-Auge and Violaine Latapie and Jean-François Deleuze and Ravi Philip Rajkumar and Deepak Gopal Shewade and Frank Bélivier and Cynthia Marie-Claire and Stéphane Jamain},
journal= {arXiv preprint arXiv:2304.03131},
year = {2023}
}